The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.

Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

scrutinized the efficacy and safety of poly (ADP-ribose) polymerase inhibitors (PARPi) as a maintenance treatment in 75 Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC). The ...

or if a person has other risk factors for ovarian cancer. Ovarian cysts often go away on their own but in some cases can cause pain and other symptoms. Home remedies, including OTC pain medications ...

Drinking green tea may increase the survival rates of some cancer patients. One study of women with ovarian cancer found that women who drank green tea were more likely to survive 3 years after ...

The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...